Pharming Group NV (PHARM.AS) stock: key figures, P/E, revenue and dividend

Health Care · Netherlands · ISIN NL0010391025

Price
1.21 EUR
Market cap
771.59 m EUR
P/E (2025)
357.95
P/S (2025)
2.05
Dividend yield
0.00 %
Net margin
0.53 %
Return on equity (ROE)
0.72 %
Return on assets (ROA)
0.40 %

Pharming Group NV financials

Fiscal year20242025
Revenue297.13 m USD376.13 m USD
Gross profit226.00 m USD286.00 m USD
Operating income-3.47 m USD27.89 m USD
EBIT-2.00 m USD18.00 m USD
Net income-11.84 m USD2.00 m USD
Diluted EPS – continuing operations-0.01 USD0.00 USD

Full history since 1996, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.